Loading organizations...
Pep2Tango Therapeutics develops next-generation unimolecular multi-agonist peptides for obesity and associated metabolic disorders. Their innovative approach creates superior multi-receptor agonists engineered for enhanced weight loss, improved tolerability, and muscle mass preservation. This strategy directly addresses key limitations of current therapeutics, aiming for more effective patient solutions.
Cristina Rondinone, Ph.D., founded Pep2Tango Therapeutics, launching the company in 2021. With leadership experience from Cellarity, Dr. Rondinone established the company to tackle significant drawbacks of existing GLP-1-based obesity therapies. Her insight focused on leveraging advanced peptide engineering to overcome these limitations, developing a refined therapeutic profile.
Pep2Tango's products target individuals with obesity and related co-morbidities seeking superior, tolerable treatments. The company’s long-term vision is to redefine metabolic disease care by delivering unimolecular multi-receptor therapies with significant clinical advantages. They aim to advance beyond current treatments, providing patients improved health outcomes and quality of life.
Pep2Tango Therapeutics has raised $1K across 1 funding round.
Pep2Tango Therapeutics has raised $1K in total across 1 funding round.
Pep2Tango Therapeutics has raised $1K across 1 funding round. Most recently, it raised $1K Series U in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2024 | $1K Series U | — | Avalon Ventures, Polaris Partners, Versant Ventures | Announced |
Pep2Tango Therapeutics has raised $1K in total across 1 funding round.
Pep2Tango Therapeutics's investors include Avalon Ventures, Polaris Partners, Versant Ventures.
Pep2Tango Therapeutics is not a technology company—it is a biotechnology company focused on developing next-generation peptide drugs for obesity and related metabolic disorders.
Pep2Tango Therapeutics is a privately-held biotech startup developing unimolecular multi-receptor agonist peptides designed to treat obesity while preserving muscle mass.[1] The company's core mission is to create next-generation weight loss therapies that address unmet medical needs in metabolic, endocrine, CNS, and cardiovascular disorders.[1]
The company serves patients with obesity and related conditions, tackling a critical problem: existing weight loss medications often cause muscle loss alongside fat loss and face manufacturing and tolerability challenges.[4] Pep2Tango's approach aims to deliver superior efficacy compared to current market leaders like tirzepatide (Zepbound) through a differentiated mechanism that combines four receptor targets into a single molecule.[1][4]
Pep2Tango was founded in 2021 by seasoned pharmaceutical executives with deep expertise in drug development.[1] The company is led by CEO and Chairperson Cristina Rondinone, Ph.D., who previously oversaw cardiometabolic drug development at AstraZeneca and served as president of startup Cellarity.[4] Chief Scientific Officer Soumitra Ghosh, Ph.D. formerly led R&D at Amylin Pharmaceuticals, a company that developed pioneering GLP-1 drugs for diabetes.[4]
The startup emerged from stealth in late 2024 backed by Versant Ventures, a prominent biotech venture firm known for launching and scaling biotech companies.[1] The founding team's vision centered on developing a "tetra-agonist"—a first-in-class approach that Rondinone described as moving beyond the conventional mono, dual, or triple agonist strategies already in development.[4]
Pep2Tango operates within the rapidly expanding obesity therapeutics market, riding the wave of GLP-1 agonist success while pushing toward next-generation solutions.[4] The company represents a broader industry trend of moving beyond first-generation weight loss drugs to address their limitations—particularly muscle loss and manufacturing complexity.
The timing is strategic: as tirzepatide and semaglutide dominate the market, biotech investors are funding differentiated approaches that promise improved efficacy and tolerability.[4] Pep2Tango's tetra-agonist strategy positions it as a potential category leader if clinical data validates preclinical findings, influencing how the industry approaches multi-target drug design for metabolic diseases.
Pep2Tango is entering IND-enabling studies with its first-in-class obesity medicine, positioning it for clinical trials in the near term.[1] The company's success hinges on translating preclinical advantages into clinical efficacy and navigating the competitive obesity therapeutics space, where multiple well-funded competitors are pursuing similar multi-target strategies.
If Pep2Tango's tetra-agonist approach proves clinically superior while maintaining safety and tolerability, it could reshape obesity treatment standards and validate the multi-receptor peptide platform for other metabolic and endocrine disorders—the company's stated long-term vision.[1]
